TETRA Technologies, Inc. logo TTI - TETRA Technologies, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 18
HOLD 13
SELL 0
STRONG
SELL 0
| PRICE TARGET: $11.00 DETAILS
HIGH: $14.00
LOW: $9.00
MEDIAN: $10.00
CONSENSUS: $11.00
UPSIDE: 62.48%

Stock News

TETRA TECHNOLOGIES, INC. REPORTS STRONG SECOND-QUARTER 2026 RESULTS

TETRA TECHNOLOGIES, INC. REPORTS STRONG SECOND-QUARTER 2026 RESULTS

SPRING, Texas, Aug. 3, 2026 /PRNewswire/ -- TETRA Technologies, Inc. ("TETRA" or the "Company") (NYSE:TTI) announced financial results for the three and six months ended June 30, 2026. Second-Quarter 2026 Financial Highlights Revenues of $185.7 million Income from continuing operations of $10.2 million, inclusive of $1.1 million of unusual charges Adjusted EBITDA of $31.9 million Net Income per share from continuing operations of $0.07, adjusted net income per share of $0.08 Launched TETRA Neptune Z-Lite, awarded a three-well Gulf of America Deepwater Project Raised $108 million of net proceeds related to the equity offering Board of Directors approved final investment decision ("FID") for the Arkansas Bromine Project Brady Murphy, TETRA's President and Chief Executive Officer, stated, "We delivered one of our strongest second-quarter and first-half financial performances in the past decade, reflecting the strength of our base business and our ability to grow in deepwater and international markets.

Aug 03, 2026 01:56 PM • prnewswire.com
Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome

Thiogenesis Receives FDA Rare Pediatric Disease Designation for TTI-0102 for the Treatment of Leigh Syndrome

San Diego, California--(Newsfile Corp. - July 13, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing novel sulfur-based thiol therapies for rare pediatric, metabolic and mitochondrial disorders, today announced that the U.S. Food and Drug Administration ("FDA") has granted Rare Pediatric Disease ("RPD") designation to its lead candidate, TTI-0102, for the treatment of Leigh syndrome. The FDA grants RPD designation to therapies intended to treat serious or life-threatening diseases that primarily affect children from birth through 18 years of age.

Jul 13, 2026 02:00 AM • newsfilecorp.com
Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

Tvardi Therapeutics' TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement

TTI-109 delivered TTI-101-equivalent exposure with improved tolerability and meaningful reductions in disease-relevant STAT3-driven immune cell populations including Th17, T follicular helper (Tfh) and B cells Company plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal (GI) diseases - subject to additional funding Company to host investor webcast today, July 7 th , at 8:30am ET HOUSTON, July 07, 2026 (GLOBE NEWSWIRE) -- Tvardi Therapeutics, Inc. (“Tvardi” or the “Company”) (NASDAQ: TVRD), a clinical-stage biopharmaceutical company focused on the development of novel, oral, small molecule therapies targeting STAT3 to treat inflammatory and proliferative diseases, today announced Phase 1 results for TTI-109, its next-generation STAT3 inhibitor. TTI-109 is a phosphate prodrug of TTI-101 designed to improve delivery and tolerability while preserving the parent compound's mechanism of action.

Jul 07, 2026 03:00 AM • globenewswire.com
TETRA TECHNOLOGIES INTRODUCES TETRA NEPTUNE Z-LITE DEEPWATER COMPLETIONS FLUID

TETRA TECHNOLOGIES INTRODUCES TETRA NEPTUNE Z-LITE DEEPWATER COMPLETIONS FLUID

Using Neptune Chemistry to Achieve Required Density With Lower Zinc Content; Awarded Three-Well 20k psi Deepwater Project in the Gulf of America With Estimated Start in 2026 SPRING, Texas, June 29, 2026 /PRNewswire/ -- TETRA Technologies, Inc. (NYSE: TTI) today announced the introduction of TETRA Neptune Z-Lite, a high-density completion fluid designed for deepwater and high-pressure well applications. The fluid system uses our patented Neptune fluid chemistry and expands the Company's completion fluids portfolio by offering up to 60% lower zinc-ion concentration than conventional zinc-based fluids while maintaining required density performance.

Jun 29, 2026 03:00 AM • prnewswire.com
Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

Thiogenesis Appoints Dr. Gilad Aharon to Its Board of Directors

San Diego, California--(Newsfile Corp. - June 17, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company"), a clinical-stage biotechnology company developing next-generation cysteamine-based therapies for rare diseases, including cystinosis and primary mitochondrial diseases, today announced the appointment of Gilad Aharon, PhD, to its Board of Directors. Dr. Aharon is a Co-Founder and Portfolio Manager at Rosalind Advisors, Inc., a Toronto-based life sciences institutional investor.

Jun 17, 2026 04:00 AM • newsfilecorp.com
VIAVI Launches TETRA MS Base Station Simulator Option for CX300 to Simplify and Speed Mission-Critical Radio Testing

VIAVI Launches TETRA MS Base Station Simulator Option for CX300 to Simplify and Speed Mission-Critical Radio Testing

Allows full testing of TETRA MS radios, including transmitter parametric measurements, call processing and BER/MER loopback without the need to place radios in T1 test mode CHANDLER, Ariz., June 15, 2026 /PRNewswire/ -- VIAVI Solutions Inc. (VIAVI) (NASDAQ: VIAV) has announced a TETRA MS radio base station simulator option for its field-portable CX300 communications service monitor.

Jun 15, 2026 02:30 AM • prnewswire.com

Price Targets